Home LiteratureArticle Details
PMID: 24336317 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Genome-wide localization of small molecules.

Nature biotechnology ·Vol. 32 ·No. 1 ·2014-01-00 ·Pages 92-6

Anders L, Guenther MG, Qi J, Fan ZP, Marineau JJ, Rahl PB, Lovén J, Sigova AA, Smith WB, Lee TI, Bradner JE, Young RA

Abstract

A vast number of small-molecule ligands, including therapeutic drugs under development and in clinical use, elicit their effects by binding specific proteins associated with the genome. An ability to map the direct interactions of a chemical entity with chromatin genome-wide could provide important insights into chemical perturbation of cellular function. Here we describe a method that couples ligand-affinity capture and massively parallel DNA sequencing (Chem-seq) to identify the sites bound by small chemical molecules throughout the human genome. We show how Chem-seq can be combined with ChIP-seq to gain unique insights into the interaction of drugs with their target proteins throughout the genome of tumor cells. These methods will be broadly useful to enhance understanding of therapeutic action and to characterize the specificity of chemical entities that interact with DNA or genome-associated proteins.

MeSH Terms
Binding Sites/genetics Chromatin/genetics DNA/genetics Genome, Human High-Throughput Nucleotide Sequencing Humans Ligands Protein Binding/genetics Proteins/genetics Transcription Factors/genetics
Chemicals
Chromatin Ligands Proteins Transcription Factors DNA
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Anders Lars
1] Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA. [2].
Guenther Matthew G
1] Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA. [2].
Qi Jun
Department of Medical Oncology, Dana-Farber Cancer Institute, Massachusetts, USA.
Fan Zi Peng
1] Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA. [2] Computational and Systems Biology Program, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Marineau Jason J
Department of Medical Oncology, Dana-Farber Cancer Institute, Massachusetts, USA.
Rahl Peter B
Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA.
Lovén Jakob
Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA.
Sigova Alla A
Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA.
Smith William B
Department of Medical Oncology, Dana-Farber Cancer Institute, Massachusetts, USA.
Lee Tong Ihn
Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA.
Bradner James E
1] Department of Medical Oncology, Dana-Farber Cancer Institute, Massachusetts, USA. [2] Department of Medicine, Harvard Medical School, Massachusetts, USA.
Young Richard A
1] Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA. [2] Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
References (43)
43 references, click to expand
  1. Epigenetic protein families: a new frontier for drug discovery.
    Nat Rev Drug Discov. 2012 Apr 13;11(5):384-400 PMID: 22498752
  2. Genome-wide transcription factor binding: beyond direct target regulation.
    Trends Genet. 2011 Apr;27(4):141-8 PMID: 21295369
  3. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
    Oncogene. 2010 Apr 22;29(16):2325-36 PMID: 20101221
  4. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p.
    Science. 1996 Apr 19;272(5260):408-11 PMID: 8602529
  5. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
    Nature. 2011 Aug 03;478(7370):524-8 PMID: 21814200
  6. Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
    J Med Chem. 2011 Jun 9;54(11):3827-38 PMID: 21568322
  7. Suppression of inflammation by a synthetic histone mimic.
    Nature. 2010 Dec 23;468(7327):1119-23 PMID: 21068722
  8. Control of the embryonic stem cell state.
    Cell. 2011 Mar 18;144(6):940-54 PMID: 21414485
  9. Application of ChIP-Seq and related techniques to the study of immune function.
    Immunity. 2011 Jun 24;34(6):830-42 PMID: 21703538
  10. Drug target deconvolution by chemical proteomics.
    Curr Opin Chem Biol. 2011 Aug;15(4):570-5 PMID: 21763176
  11. BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
    Cell. 2011 Sep 16;146(6):904-17 PMID: 21889194
  12. Histone H3K27ac separates active from poised enhancers and predicts developmental state.
    Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21931-6 PMID: 21106759
  13. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
    Genome Biol. 2009;10(3):R25 PMID: 19261174
  14. c-Myc regulates transcriptional pause release.
    Cell. 2010 Apr 30;141(3):432-45 PMID: 20434984
  15. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.
    Nature. 2012 Jan 04;481(7381):389-93 PMID: 22217937
  16. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
    Mol Cancer Ther. 2010 Apr;9(4):920-8 PMID: 20354122
  17. Mediator and cohesin connect gene expression and chromatin architecture.
    Nature. 2010 Sep 23;467(7314):430-5 PMID: 20720539
  18. Circuitry and dynamics of human transcription factor regulatory networks.
    Cell. 2012 Sep 14;150(6):1274-86 PMID: 22959076
  19. Protein methyltransferases as a target class for drug discovery.
    Nat Rev Drug Discov. 2009 Sep;8(9):724-32 PMID: 19721445
  20. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
    Nature. 2011 Oct 02;478(7370):529-33 PMID: 21964340
  21. Transcription-dependent dynamic supercoiling is a short-range genomic force.
    Nat Struct Mol Biol. 2013 Mar;20(3):396-403 PMID: 23416947
  22. Selective inhibition of tumor oncogenes by disruption of super-enhancers.
    Cell. 2013 Apr 11;153(2):320-34 PMID: 23582323
  23. A chromatin landmark and transcription initiation at most promoters in human cells.
    Cell. 2007 Jul 13;130(1):77-88 PMID: 17632057
  24. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.
    Nat Biotechnol. 2011 Mar;29(3):255-65 PMID: 21258344
  25. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.
    Bioinformatics. 2010 Jan 1;26(1):139-40 PMID: 19910308
  26. A unique chromatin signature uncovers early developmental enhancers in humans.
    Nature. 2011 Feb 10;470(7333):279-83 PMID: 21160473
  27. Evaluating genome-scale approaches to eukaryotic DNA replication.
    Nat Rev Genet. 2010 Oct;11(10):673-84 PMID: 20811343
  28. Cancer genetics and epigenetics: two sides of the same coin?
    Cancer Cell. 2012 Jul 10;22(1):9-20 PMID: 22789535
  29. Selective inhibition of BET bromodomains.
    Nature. 2010 Dec 23;468(7327):1067-73 PMID: 20871596
  30. Model-based analysis of ChIP-Seq (MACS).
    Genome Biol. 2008;9(9):R137 PMID: 18798982
  31. Cancer epigenomics: beyond genomics.
    Curr Opin Genet Dev. 2012 Feb;22(1):50-5 PMID: 22402447
  32. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.
    Trends Immunol. 2012 Nov;33(11):563-70 PMID: 22867873
  33. The transcriptional and signalling networks of pluripotency.
    Nat Cell Biol. 2011 May;13(5):490-6 PMID: 21540844
  34. Determinants and dynamics of genome accessibility.
    Nat Rev Genet. 2011 Jul 12;12(8):554-64 PMID: 21747402
  35. Chromatin affinity-precipitation using a small metabolic molecule: its application to analysis of O-acetyl-ADP-ribose.
    Cell Mol Life Sci. 2012 Feb;69(4):641-50 PMID: 21796450
  36. Chromatin connections to pluripotency and cellular reprogramming.
    Cell. 2011 Jun 10;145(6):835-50 PMID: 21663790
  37. Transcription forms and remodels supercoiling domains unfolding large-scale chromatin structures.
    Nat Struct Mol Biol. 2013 Mar;20(3):387-95 PMID: 23416946
  38. Chromatin immunoprecipitation and microarray-based analysis of protein location.
    Nat Protoc. 2006;1(2):729-48 PMID: 17406303
  39. RNA polymerase II elongation control.
    Annu Rev Biochem. 2012;81:119-43 PMID: 22404626
  40. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells.
    Cell. 2008 Aug 8;134(3):521-33 PMID: 18692474
  41. Next-generation genomics: an integrative approach.
    Nat Rev Genet. 2010 Jul;11(7):476-86 PMID: 20531367
  42. Identification of a primary target of thalidomide teratogenicity.
    Science. 2010 Mar 12;327(5971):1345-50 PMID: 20223979
  43. Charting histone modifications and the functional organization of mammalian genomes.
    Nat Rev Genet. 2011 Jan;12(1):7-18 PMID: 21116306
Article Info
Journal
Nature biotechnology
Abbr.
Nat Biotechnol
ISSN
1546-1696
Published
2014-01-00
Epub
2013-00-15
Pages
92-6
Language
English
Region
United States
NLM ID
9604648
PMCID
PMC4189815
Subset
IM
Grants
NHGRI NIH HHS · R01 HG002668 · United States
NHGRI NIH HHS · HG002668 · United States
NCI NIH HHS · P01 CA109901 · United States
NCI NIH HHS · R01 CA146445 · United States
NCI NIH HHS · CA146445 · United States
NCI NIH HHS · CA109901 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com